Biohaven Pharma (BHVN) Misses Q1 EPS by 47c

Biohaven Pharma (NYSE: BHVN) reported Q1 EPS of ($2.17), $0.47 worse than the analyst estimate of ($1.70).

For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Rubrik Inc (RBRK) PT Raised to $120 at Oppenheimer; Sees Another 'Beat and Raise'
• SuperCom wins third Texas electronic monitoring contract